Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial

Kassoum Kayentao¹, Ogobara K Doumbo¹, Louis K Pénali², André T Offianan², Kirana M Bhatt³, Joshua Kimani³, Antoinette K Tshefu⁴, Jack HT Kokolomami⁵, Michael Ramharter⁵, Pablo Martinez de Salazar⁵, Alfred B Tiono⁸, Alphonse Ouédraogo⁸, Maria Dorina G Bustos⁹, Frederick Quicho⁹, Isabelle Borghini-Fuhrer¹⁰, Stephan Dupac⁵, Chang-Sik Shin¹¹ and Lawrence Fleckenstein¹²

Abstract

Background: Children are most vulnerable to malaria. A pyronaridine-artesunate pediatric granule formulation is being developed for the treatment of uncomplicated Plasmodium falciparum malaria.

Methods: This phase III, multi-center, comparative, open-label, parallel-group, controlled clinical trial included patients aged ≤12 years, bodyweight ≥5 to <25 kg, with a reported history of fever at inclusion or in the previous 24 h and microscopically-confirmed uncomplicated P. falciparum malaria. Patients were randomized (2:1) to pyronaridine-artesunate granules (60/20 mg) once daily or artemether-lumefantrine crushed tablets (20/120 mg) twice daily, both dosed by bodyweight, orally (liquid suspension) for three days.

Results: Of 535 patients randomized, 355 received pyronaridine-artesunate and 180 received artemether-lumefantrine. Day-28 adequate clinical and parasitological response (ACPR), corrected for re-infection using polymerase chain reaction (PCR) genotyping (per-protocol population) was 97.1% (329/339; 95% CI 94.6, 98.6) for pyronaridine-artesunate; 98.8% (165/167; 95% CI 95.7, 99.9) for artemether-lumefantrine. The primary endpoint was achieved: pyronaridine-artesunate PCR-corrected day-28 ACPR was statistically significantly >90% (P < .0001). Pyronaridine-artesunate was non-inferior to artemether-lumefantrine: treatment difference -1.8% (95% CI -4.3 to 1.6). The incidence of drug-related adverse events was 37.2% (132/355) with pyronaridine-artesunate, 44.4% (80/180) with artemether-lumefantrine. Clinical biochemistry results showed similar mean changes versus baseline in the two treatment groups. From day 3 until study completion, one patient in each treatment group had peak alanine aminotransferase (ALT) >3 times the upper limit of normal (ULN) and peak total bilirubin >2xULN (i.e. within the Hy’s law definition).

Conclusions: The pyronaridine-artesunate pediatric granule formulation was efficacious and was non-inferior to artemether-lumefantrine. The adverse event profile was similar for the two comparators. Pyronaridine-artesunate should be considered for inclusion in paediatric malaria treatment programmes.

Trial registration: ClinicalTrials.gov: identifier NCT00541385

Keywords: Pyronaridine-artesunate, Artemether-lumefantrine, Malaria, Plasmodium falciparum, Pediatric
Background

Plasmodium falciparum malaria kills approximately 850,000 children annually, most are under five years old [1,2]. The World Health Organization (WHO) generally recommends artemisinin-containing combination therapy (ACT) for the treatment of P. falciparum malaria [3]. However, of those medicines included on the WHO list of prequalified medicinal products, only artemether-lumefantrine dispersible tablets and artesunate-amodiaquine water-soluble tablets are available for oral liquid administration to children [4]. Clearly, there is a need for new formulations of ACT specifically formulated for pediatric use.

Pyronaridine-artesunate (3:1 ratio) is an ACT being developed for the treatment of uncomplicated P. falciparum and Plasmodium vivax malaria [5-7]. In two Phase III trials of pyronaridine-artesunate tablets, both conducted in adults and children in Africa and Asia with P. falciparum malaria, day-28 adequate clinical and parasitological response (ACPR) rates in the per-protocol population were 99.5% (780/784) and 99.2% (743/749) when corrected for re-infection with polymerase chain reaction genotyping (PCR-corrected) [5,6]. Pyronaridine-artesunate was non-inferior to artesunate-lumefantrine and mefloquine plus artesunate, respectively [5,6]. The adverse event profile of pyronaridine-artesunate in these trials has been generally favorable, though liver transaminases were increased in some patients [5,6].

Children are most vulnerable to malaria [1,2,8-10] and adverse events are potentially more serious in this patient population. A pyronaridine-artesunate pediatric granule formulation was included in the development programme. A Phase II study in children described similar pharmacokinetics between the tablet and granule formulations [11]. This paper reports outcomes from a Phase III comparative, open-label, randomized, multi-center clinical study assessing the safety and efficacy of a fixed-dose oral pyronaridine-artesunate granule formulation (60/20 mg) versus artesunate-lumefantrine crushed tablets in infants and children with acute uncomplicated P. falciparum malaria. The primary efficacy outcome of this trial was to demonstrate >90% efficacy of pyronaridine-artesunate granules in children with P. falciparum mono-infection evaluated using PCR-corrected day-28 ACPR in the per-protocol population [12]. A secondary efficacy outcome was to compare the efficacy of pyronaridine-artesunate granules with that of artesunate-lumefantrine crushed tablets.

Methods

Ethics statement

The protocol was approved by each study center’s independent ethics committee and the study was conducted in accordance with the Declaration of Helsinki (Tokyo 2004), Good Clinical Practice, and applicable regulations. Informed written or witnessed oral consent was obtained from all patients’ parents/guardians; assent was required from children able to understand the study.

Study design

This multi-center, comparative, randomized, open-label, parallel-group clinical trial followed WHO guidelines [12]. Study drugs were pyronaridine-artesunate granules (60/20 mg) supplied in aluminium sachets (Shin Poong Pharmaceutical Company, Ltd., Ansan, Korea), and artesunate-lumefantrine tablets (20/120 mg), supplied in blister packs (Novartis SA, Basel, Switzerland). Patients were recruited from local hospitals and clinics at seven centers: Koupèla, Burkina Faso; Kinshasa, Democratic Republic of Congo; Lambaréné, Gabon; Anonkoua-koute, Côte d’Ivoire; Siaya, Kenya; Bougoula, Mali; and Puerto Princesa, the Philippines.

Patients

Eligible subjects were of either sex, ≤12 years old, with a bodyweight ≥ 5 kg and < 25 kg (with no evidence of severe malnutrition), a reported history of fever at inclusion or within the previous 24 h, and microscopically-confirmed uncomplicated P. falciparum mono-infection (sexual parasite density 1,000–200,000 μL⁻¹ blood). If applicable, a negative pregnancy test was required. Subjects were excluded if they had: signs and symptoms of severe/complicated malaria [13]; mixed Plasmodium infection; severe vomiting (> 3 times in the previous 24 h); severe diarrhoea (≥ 3 watery stools per day); other clinically significant disorders, including hepatitis or HIV infection; other febrile conditions; hepatic/renal impairment; electrolyte imbalance; anemia (hemoglobin <8 g/dL); hypersensitivity/allergy to study drugs; anti-malarial therapy in the previous two weeks, an investigational drug within four weeks, or any drug metabolized by cytochrome enzyme CYP2D6; participated previously in pyronaridine-artesunate clinical studies.

Randomization and blinding

The sponsor provided a computer-generated randomization schedule. Patients were randomized 2:1 to pyronaridine-artesunate or artesunate-lumefantrine. Randomization numbers were assigned in ascending order. Individually numbered treatment packs of similar appearance were masked on allocation. Clinical assessments and drug administration were performed by different clinical personnel. Drugs were given open-label. The study sponsor remained blinded to treatment allocation.

Treatments

Study drugs were given orally for 3 days (days 0, 1 and 2), dosed according to bodyweight. All doses were directly
observed. Pyronaridine-artesunate was given once daily: ≥5 to <9 kg, one sachet; 9 to <17 kg, two sachets; 17 to <25 kg, three sachets (dose range 6.7/2.2 to 13.3/4.4 mg/kg/dose). Artemether-lumefantrine was given twice daily: ≥5 to <15 kg, one tablet; 15 to <25 kg, two tablets (dose range 1.3/8.0 to 4.0/24.0 mg/kg/dose); the second day-0 dose was 8 h after the first dose, the first day-1 dose was 24 h after the first day-0 dose, with all subsequent doses 12 h apart.

Oral suspensions were prepared immediately before dosing. Pyronaridine-artesunate granules were stirred into 50 mL of water, milk, or soup. Artemether-lumefantrine tablets were crushed to coarse particles, added to 50 mL of water and shaken to a uniform suspension. Residual drug was given by adding 100 mL of water to the dosing cup. Artemether-lumefantrine was given with food or milk as per local guidelines. Vomiting within 30 minutes following the first drug dose resulted in re-dosing. Vomiting after repeat dosing or any subsequent dose resulted in study withdrawal and treatment with rescue medication (as per local guidelines).

Procedures
At screening, a medical history was taken and a physical examination performed. Eligible patients were hospitalized from day 0 to day 3, with follow-up at days 7, 14, 21, 28, 35, and 42. Temperature was taken at screening, every 8 h over ≥72 h following the first dose or until two normal readings between 7 and 25 h apart, then at each visit or as clinically indicated. All study sites were provided with equipment which was used solely for the rapid analysis of biochemical and hematological samples obtained from the subjects evaluated for inclusion in the trial or samples obtained during the trial. Venous blood samples were taken for clinical biochemistry and hematology at screening, days 3, 7, 28, and 42; urinalysis was performed at screening. Electrocardiographs (ECG) were done at screening and day 2, and if indicated at days 7, 14, and 28.

Parasitological assessments were conducted according to WHO guidelines [12]. Venous blood samples for asexual and gametocyte parasite counts were taken before each dose, every 8 h (±1 h) following first dose administration for ≥72 h or until parasite clearance (two consecutive negative readings 7 to 25 h apart), and at subsequent visits. Giemsa-stained thick blood films were examined independently by two microscopists with the arithmetic mean recorded. A thin blood smear for species identification was examined at screening and from day 7 for all parasitological blood samples.

Following parasite reappearance, recrudescence and re-infection were distinguished by PCR genotyping performed at a central laboratory (Swiss Tropical and Public Health Institute, Basel, Switzerland). Using P. falciparum genes msp1, msp2, and glurp, recrudescence was defined as at least one matching allelic band in all markers between baseline and post-day-7 samples [14,15]. There were no amendments to the original study protocol.

Endpoints
The primary efficacy endpoint was pyronaridine-artesunate day-28 PCR-corrected ACPR >90%. The main secondary efficacy endpoint was non-inferiority of pyronaridine-artesunate to arteether-lumefantrine for day-28 PCR-corrected ACPR [12]. Treatment failures were classified as early treatment failure, late clinical failure, and late parasitological failure according to WHO criteria [12].

Other secondary efficacy outcomes were: day-28 crude (non-PCR corrected) ACPR; day-42 PCR-corrected and crude ACPR; parasite clearance time (time from first dose until afebrile, i.e. two consecutive negative readings taken between 7 and 25 h apart); fever clearance time (time from first dose to afebrile, i.e. two consecutive normal readings taken between 7 and 25 h apart); and the proportion of patients with parasitemia clearance or fever clearance on days 1, 2, and 3. Exploratory efficacy outcomes were: gametocyte density and proportion of patients with gametocytes; and gametocyte clearance time (defined as for parasite clearance time).

Safety outcomes were: adverse events, categorized using MedDRA (version, 10.1); laboratory abnormalities graded using the Division of Microbiology and Infectious Diseases Toxicity Scale (February, 2003); and ECG abnormalities.

Sample size
A 95% cure rate was assumed for both treatments. For the primary efficacy endpoint, 320 evaluable patients in the pyronaridine-artesunate group provided 91% power to reject the null hypothesis (i.e. day-28 cure rate ≤90%) using a 1-sided exact binomial test with a nominal significance level of 2.5%. For the main secondary efficacy endpoint, 480 evaluable patients randomized 2:1 provided >99% power to demonstrate non-inferiority of pyronaridine-artesunate versus arteether-lumefantrine with a non-inferiority limit of 10%. Allowing for a 10% drop out rate, target recruitment was 534 subjects (356 pyronaridine-artesunate, 178 arteether-lumefantrine).

Statistical analysis
The intent-to-treat population included all randomized subjects who received any study medication and was the same as the safety population. The per-protocol population included patients that received a full course of study medication, had a known day-28 primary endpoint, and did not violate the protocol so as to impair evaluation of the primary endpoint.
The primary efficacy endpoint was evaluated in the per-protocol population using the exact binomial test (significance limit ≤ 0.025). The associated exact (Pearson–Clopper) 2-sided 95% confidence interval (CI) was presented. The analysis was repeated for the intent-to-treat population. The primary efficacy endpoint was summarized by center, age category (<1 year, 1–<5 years, 5–12 years), gender, previous episode of malaria (yes/no), and actual pyronaridine-artesunate dose (7.2/2.4 to 8.5/2.8 mg/kg, >8.5/2.8 to 9.5/3.2 mg/kg, >9.5/3.2 to 11.0/3.7 mg/kg, and >11.0/3.7 to 13.8/4.6 mg/kg).

The main secondary efficacy endpoint was evaluated in the per-protocol population. Pyronaridine-artesunate was non-inferior to artemether-lumefantrine if the lower limit of the 2-sided 95% CI (Newcombe–Wilson score method without continuity correction) for the difference between treatments was not lower than −10%. If pyronaridine-artesunate was non-inferior, superiority was tested using 2-sided Chi-square test (significance limit < 0.05). No multiplicity testing adjustment was required. The analysis was repeated for the intent-to-treat population, day-28 crude ACPR and day-42 PCR-corrected and crude ACPR.

All other analyses were presented for the intent-to-treat population. A post-hoc Kaplan–Meier analysis of recrudescence rate and re-infection rate was conducted and treatments compared using the log-rank test. Patients who did not have the event (recrudescence or re-infection) reported were censored at the last available parasite assessment date. In addition, patients with major protocol deviations were censored at the time of the deviations if they did not have the event before that time.

| 1013 subjects screened:                      | 478 ineligible:                   |
|---------------------------------------------|-----------------------------------|
| 146 (14.4) Burkina Faso                     | 120 Negative parasitemia           |
| 155 (15.3) DR Congo                        | 89 Hemoglobin <8 g/dL              |
| 134 (13.2) Gabon                           | 75 Parasitemia <1000 µL^-1        |
| 135 (13.3) Ivory Coast                      | 54 Mixed Plasmodium infection      |
| 97 (9.6) Kenya                              | 31 Parasitemia >200,000 µL^-1     |
| 322 (31.8) Mali                             | 18 Prior antimalarial              |
| 24 (2.4) Philippines                        | 15 Abnormal liver enzymes          |
|                                             | 14 Abnormal electrocardiograph     |
|                                             | 14 High white blood cell count     |
|                                             | 12 Refusal of consent              |
|                                             | 40 Other reasons (≥5 patients)     |
|                                             | 4 Patients >1 reason               |

| 535 randomized to treatment:                | 355 pyronaridine-artesunate       |
|---------------------------------------------|-----------------------------------|
| 28 (5.2) Burkina Faso                      | (intent-to-treat population)      |
| 84 (15.7) DR Congo                         |                                   |
| 80 (15.0) Gabon                            |                                   |
| 107 (20.0) Ivory Coast                      |                                   |
| 86 (16.1) Kenya                            |                                   |
| 130 (24.3) Mali                            |                                   |
| 20 (3.7) Philippines                       |                                   |

| 38 (21.1) did not complete study:           | 167 (92.8) analyzed               |
|---------------------------------------------|-----------------------------------|
| 32 (17.8) reinfection/malaria               | (per-protocol population)        |
| 3 (1.7) adverse event                       |                                   |
| 1 (0.6) lost to follow-up                   |                                   |
| 2 (1.1) consent withdrawn                   |                                   |

| 31 (6.1) No primary efficacy endpoint       |                                   |
| 6 (3.3) Incomplete treatment course         |                                   |
| 5 (2.8) Received <80% of total dose         |                                   |
| 1 (0.6) Prohibited medication               |                                   |
| 5 (2.8) Patients with >1 reason             |                                   |

All values are n (%).
Parasite, fever and gametocyte clearance times were summarized using Kaplan–Meier estimates and treatment groups compared using the log-rank test. Patients without parasite or fever clearance within 72 h after the first drug dose were censored at that time point. The proportion of subjects with parasite, fever, and gametocyte clearance on days 1, 2 and 3 was calculated using Kaplan–Meier estimates. Statistical analysis was performed using SAS Version 9.1.3.

Results

Patients

Between November 2007 and September 2008, 355 patients were randomized to pyronaridine-artesunate, 180 to artemether-lumefantrine (Figure 1). All randomized patients were included in the intent-to-treat and safety populations. Baseline demographic and clinical characteristics were similar between the two treatment groups (Table 1).

Table 1 Demographic and clinical characteristics of the intent-to-treat population at screening

| Characteristic                  | Pyronaridine-artesunate | Artemether-lumefantrine |
|--------------------------------|-------------------------|-------------------------|
|                                | n = 355                 | n = 180                 |
| Male, n (%)                    | 177 (49.9)              | 84 (46.7)               |
| Mean age, years (SD) [range]   | 49 (2.5) [0.3–11]       | 53 (2.5) [0.3–12]       |
| <1 year, n (%)                 | 12 (3.4)                | 3 (1.7)                 |
| 1–<5 years, n (%)              | 148 (41.7)              | 69 (38.3)               |
| S–12 years, n (%)              | 195 (54.9)              | 108 (60.0)              |
| Ethnicity, n (%)               |                         |                         |
| Black                          | 342 (96.3)              | 172 (95.6)              |
| Asian/Oriental                 | 13 (3.7)                | 8 (4.4)                 |
| Mean weight, kg (SD) [range]   | 16.3 (4.1) [6.0–24.8]   | 17.1 (4.4) [7.2–24.9]   |
| Mean body mass index, kg/m² (SD) [range] | 15.0 (2.2) [6.0–24.5] 15.1 (2.3) [10.7–25.0] |
| Geometric mean asexual parasites per µL | 18565.9                | 18798.3                |
| (95% CI)                       | (16005.9, 21535.4)      | (15243.1, 23182.7)      |
| Patients with gametocytes, n (%) | 43 (12.1)               | 25 (13.9)               |
| Temperature, °C                | 38.0 (1.1) [35.9–41.5]  | 37.8 (1.1) [35.4–41.0]  |
| Fever at screening, n (%)      | 230 (65.0)              | 107 (59.4)              |
| No previous malaria infection, n (%) | 130 (36.7)              | 59 (32.8)               |
| Malaria in last 12 months, n (%) |                         |                         |
| None                           | 143 (41.1)              | 65 (36.7)               |
| 1                              | 65 (18.7)               | 34 (19.2)               |
| 2                              | 56 (16.1)               | 35 (19.8)               |
| ≥2                             | 84 (24.1)               | 43 (24.3)               |

* Malaria in last 12 months; status was unknown for 10 patients.

Efficacy

The primary efficacy endpoint was achieved. Pyronaridine-artesunate day-28 PCR-corrected ACPR in the per-protocol population was 97.1% (329/339; 95% CI 94.6, 98.6); statistically significantly >90% (P < .0001; Table 2). The intent-to-treat analysis was supportive of the primary analysis (P = .0077; Table 3).

There were no statistical differences in the primary efficacy outcome observed by age, center, gender, or previous episode of malaria. However, there were some numerical differences by age and by dose that require further evaluation (see discussion). The efficacy of pyronaridine-artesunate for children aged <1 year was 81.8% (9/11; 95% CI 48.2–97.7), for children ≥1–<5 years was 95.7% (135/141; 95% CI 91.0–98.4) and for children 5–12 years was 98.9% (185/187; 95% CI 96.2–99.9) (Additional file 1). The efficacy rate for a pyronaridine-artesunate dose of ≤8.5:2.8 mg/kg was 92.2% (107/116; 95% CI 85.8, 96.4); for >8.5:2.8 to 9.5:3.2 mg/kg, 100.0% (100/100; 95% CI 96.4, 100); for >9.5:3.2 to 11.0:3.7 mg/kg, 100.0% (97/97; 95% CI 96.3, 100); and for >11.0:3.7 mg/kg 96.2% (25/26; 95% CI 80.4, 99.9). Day-28 PCR-corrected ACPR for individual study centers was between 92.8% and 100% (Additional file 1).

Non-inferiority of pyronaridine-artesunate to artemether-lumefantrine was concluded for day-28 PCR-corrected ACPR in the per-protocol population (Table 2). Non-inferiority was also demonstrated for day-28 crude ACPR and day-42 PCR-corrected and crude ACPR in the per-protocol population (Table 2) and for outcomes in the intent-to-treat population (Table 3).

In the intent-to-treat population (Table 3), at day 28, data were available for 97.2% (345/355) of patients in the pyronaridine-artesunate group, with 10 cases of recrudescence and 27 cases of re-infection, i.e. 10.7% (37/345) of patients with data at this time point had parasite re-appearance; for artemether-lumefantrine, data were available for 96.7% (174/180) of patients with 2 cases of recrudescence and 21 cases of re-infection, i.e. 13.2% (23/174) of patients with data at this time point had parasite reappearance.

At day 42 in the intent-to-treat population (Table 3), data were available for 96.6% (343/355) of patients in the pyronaridine-artesunate group, with 19 cases of recrudescence and 60 cases of re-infection, i.e. 23.0% (79/343) of patients with data at this time point had parasite re-appearance; for artemether-lumefantrine, data were available for 96.7% (174/180) of patients with 6 cases of recrudescence and 32 cases of re-infection, i.e. 21.8% (38/174) of patients with data at this time point had parasite reappearance.

Kaplan–Meier analysis (intent-to-treat population) showed no difference between the two treatment groups for recrudescence rate (P = .53, log rank test; Figure 2a), or re-infection rate (P = .77, log rank test; Figure 2b).
Additional file 2 shows median asexual parasite, fever and gametocyte clearance times and the proportion of patients with clearance at days 1, 2, and 3. Median time to parasite clearance was shorter with pyronaridine-artesunate (24.1 h; 95% CI 24.0, 24.1) versus artemether-lumefantrine (24.2 h; 95% CI 24.1, 32.0; \(P = .02\), log-rank test; Figure 3a). Anti-pyretic medication was taken by 220/355 (62.0%) patients in the pyronaridine-artesunate group and 118/180 (65.6%) in the artemether-lumefantrine group. Median fever clearance time was marginally shorter with pyronaridine-artesunate (8.1 h; 95% CI 8.0, 8.1) versus artemether-lumefantrine (8.1 h; 95% CI 8.0, 15.8; \(P = .049\), log rank test; Figure 3b). At baseline, 13.1% (70/535) of patients had gametocytes. For those patients who had gametocyte clearance by day 3, median gametocyte clearance time was similar between the treatment groups (\(P = .48\), log-rank test). Complete gametocyte clearance was achieved between day 41 and day 44 in the pyronaridine-artesunate group and between days 31 and 40 in the artemether-lumefantrine group. In the pyronaridine-artesunate group a total 26.8% (95/354) patients had post-baseline gametocytes versus 24.7% (44/178) with artemether-lumefantrine. New occurrences of gametocytes in patients that had none at baseline occurred in 15.0% (53/354) of patients in the pyronaridine-artesunate group and 11.2% (20/178) in the artemether-lumefantrine group.

During follow-up, there were five cases of *P. ovale* (three in the pyronaridine-artesunate group); all occurred...
on or after day 28. There were two cases of *P. malariae*, occurring at day 35 and day 42 (both in the artemether-lumefantrine group). There were no cases of *P. vivax* infection. All cases of non-falciparum malaria were treated as per local guidelines.

### Safety

Mean total drug exposure was 27.7/9.2 mg/kg (average daily dose 9.2/3.1 mg/kg) for pyronaridine-artesunate and 11.5/68.9 mg/kg (average daily dose 3.8/23.0 mg/kg) for artemether-lumefantrine.

Adverse events of any cause were experienced by 285/355 (80.3%) patients in the pyronaridine-artesunate, and 143/180 (79.4%) patients in the artemether-lumefantrine group (Table 4). Adverse events thought to be drug related occurred in 132/355 (37.2%) patients in the pyronaridine-artesunate group and 80/180 (44.4%) in the artemether-lumefantrine group. There were no clinically important differences in the nature or incidence of adverse events between the two study groups (Table 4).

There were no deaths. One serious adverse event (complicated malaria) occurred in a 2-year-old male,
resulting in study withdrawal on day 0 (11 h 20 mins after inclusion) after receiving one dose of pyronaridine-artesunate. He was treated with intramuscular artemether (day 1 and days 6–10) and intravenous quinine (days 1–5) and recovered well. The investigator noted this adverse event as unrelated to study treatment. In both treatment groups, 1.7% of patients had adverse events leading to drug discontinuation and study withdrawal: six patients receiving pyronaridine-artesunate (five with vomiting, one with malaria) and three receiving artemether-lumefantrine (three with vomiting).

Hematology results showed similar mean changes from baseline in the two treatment groups consistent with effective anti-malarial therapy. Mean hemoglobin concentrations decreased by −0.60 to −0.68 g/dL on day 3 and recovered by Day 28 (Additional file 3), with corresponding changes in hematocrit and red blood cell count. Mean increases in reticulocyte count of 0.5–0.6% were seen on Day 7 (Additional file 3). There were no other clinically relevant hematological changes.

Clinical biochemistry results showed similar mean changes versus baseline in the two treatment groups (Additional file 3). From day 3 until study completion, one patient in each treatment group triggered a potential Hy’s law case (i.e. peak alanine aminotransferase [ALT] >3 times the upper limit of normal [ULN] and peak total bilirubin >2xULN) [16]. In the patient receiving pyronaridine-artesunate, peak ALT was 704 U/L (day 7), though alkaline phosphatase (ALP) was elevated at screening (210 U/L), suggesting a possible underlying cause. In the patient receiving artemether-lumefantrine, peak ALT was
759 U/L (day 3), and alkaline phosphatase was normal (5 U/L) at screening. One additional patient in the artemether-lumefantrine group had peak AST >3xULN and peak total bilirubin >2xULN. In all cases, values were within normal limits at the final assessment (days 28–42).

There were no clinically important changes in any other laboratory parameters.

There were no post-baseline clinically important abnormal ECG results. One patient in the artemether-lumefantrine group had an adverse event of arrhythmia, considered possibly drug related.

**Discussion**

In children with uncomplicated *P. falciparum* malaria treated with pyronaridine-artesunate granules, day-28 PCR-corrected ACPR was 97.1% (95% CI 94.6, 98.6) in the per-protocol population. This is consistent with the high efficacy rates reported with pyronaridine-artesunate tablets in Phase III trials conducted in children and adults with *P. falciparum* malaria [5,6]. Introduction of a new antimalarial requires an efficacy of >95% [3]. Statistically this trial was powered to show whether a cure rate of >90% was achieved. This was because of practical reasons in determining a reasonable sample size and the assumption that cure rates would be around 95%. Reaching an actual cure rate of 95% with a confidence interval of 95% ± Δ only allows you to demonstrate that the cure rate is >95% – Δ. Thus, with an actual cure rate of 95% it was deemed realistic to demonstrate that the cure rate is >90%. The sample size calculation was based on these assumptions.
Pyronaridine-artesunate was highly efficacious across all seven study centers and was equally effective across all age groups (Additional file 1). However, the primary efficacy outcome was not quite met in the youngest age group (81.8%; 95% CI 48.2–97.7), though only 11 children <1 year old were analyzed in the per-protocol population for pyronaridine-artesunate. In children aged 1–5 years, outcomes were similar to the older children and met the primary endpoint. Thus, further data are needed to assess to efficacy of pyronaridine-artesunate in very young children (<1 year old). Studies in very young children should only be conducted after more extensive clinical use in older children and adults to demonstrate safety. A study protocol could be envisaged where adults/older children are first recruited, and once a safety review of that population is complete, recruitment could be extended to a cohort of children more than two years of age and if safety is satisfactory in this group, finally, a cohort of very young children from 6 months old could be included in the study.

The data suggested an improved efficacy with pyronaridine-artesunate doses higher than 8.5:2.8 mg/kg/day, using PCR-corrected cure rates. These data are in contrast to a Phase II trial, in which PCR-corrected efficacy was 100% for pyronaridine-artesunate dose groups of 6:2 mg/kg, 9:3 mg/kg and 12:4 mg/kg [11]. Population pharmacokinetic data for pyronaridine indicate a larger volume of distribution in children versus adults, resulting in lower concentrations over time (author’s unpublished data). The limited immunity of children under 5 years of age to P. falciparum could also make this population more sensitive to dose–response effects. These findings will be examined more closely in a report on the population pharmacokinetics across the Phase III trials.

Pyronaridine-artesunate efficacy in children was non-inferior to that of artemether-lumefantrine; consistent with previous findings in children and adults [5]. There were no differences between treatment groups in the rate of recrudescence or re-infection (Figure 2). In the previous Phase III study (tablet formulation), pyronaridine-artesunate showed a significantly greater post-treatment prophylactic effect versus artemether-lumefantrine at day 42 (P = .007) [5]. This might result from differences in transmission rates between the two studies, or because in the previous study 56.7% of patients were >12 years old with no children under 5 years. Their greater immunity to P. falciparum may have contributed to a more sustained prophylactic effect.

As expected, both treatments reduced parasitemia rapidly. Parasite clearance time was shorter with pyronaridine-artesunate versus artemether-lumefantrine (P = .02). This was seen previously [5], and in studies of other forms of ACT containing dihydroartemisinin or artesunate compared with artemether [17,18]. Artesunate is converted more rapidly and completely than artemether to the active form dihydroartemisinin and has greater oral availability on the first day of treatment [19].

The effect of fat for optimizing artemether-lumefantrine absorption is well known and in this study we allowed each center to follow their local recommendations with regard to food or milk at the point of administration. Although this potentially introduces some variability, artemether-lumefantrine efficacy was high across all centers included in the study. There is no significant food effect with pyronaridine-artesunate which can be given regardless of food intake.

Both study treatments were generally well tolerated. Adverse events with pyronaridine-artesunate were consistent with those observed for both components given as monotherapy [20–23], and with previous clinical trials of the fixed-dose combination [5–7,11]. There were no clinically relevant differences in adverse events according to drug treatment or age group.

### Table 4 Adverse events in the intent-to-treat (safety) population

| Outcome                        | Pyronaridine-artesunate | Artesunate-lumefantrine |
|--------------------------------|-------------------------|--------------------------|
| Adverse event of any cause*    | 285 (80.3)              | 143 (79.4)               |
| Cough                          | 44 (12.4)               | 28 (15.6)                |
| Upper respiratory tract infection | 42 (11.8)             | 19 (10.6)                |
| Anemia                         | 34 (9.6)                | 14 (7.8)                 |
| Platelets increased            | 33 (9.3)                | 19 (10.6)                |
| Blood glucose decreased        | 32 (9.0)                | 19 (10.6)                |
| Bronchitis                     | 28 (7.9)                | 10 (5.6)                 |
| Vomiting                       | 25 (7.0)                | 8 (4.4)                  |
| Pyrexia                        | 23 (6.5)                | 8 (4.4)                  |
| Blood albumin decreased        | 21 (5.9)                | 16 (8.9)                 |
| Influenza-like illness         | 19 (5.4)                | 8 (4.4)                  |
| Drug-related adverse eventsb   | 132 (37.2)              | 80 (44.4)                |
| Blood glucose decreased        | 29 (8.2)                | 15 (8.3)                 |
| Platelet count increased       | 27 (7.6)                | 14 (7.8)                 |
| Blood albumin decreased        | 19 (5.4)                | 16 (8.9)                 |
| Anemia                         | 15 (4.2)                | 11 (6.1)                 |
| Blood potassium increased      | 15 (4.2)                | 6 (3.3)                  |
| Hemoglobin decreased           | 15 (4.2)                | 6 (3.3)                  |
| Upper respiratory tract infection | 14 (3.9)               | 5 (2.8)                  |
| AST increased                  | 14 (3.9)                | 7 (3.9)                  |
| Hematocrit decreased           | 14 (3.9)                | 5 (2.8)                  |
| Vomiting                       | 7 (2.0)                 | 6 (3.3)                  |
| Blood creatinine decreased     | 7 (2.0)                 | 7 (3.9)                  |

All values are n (%). AST, aspartate aminotransferase.

* Experienced by ≥5% of patients in either treatment group.

b Experienced by ≥3% of patients in either treatment group.
The incidence of peak ALT >3xULN plus peak total bilirubin >2xULN was 0.3% (1/355) in the pyronaridine-artesunate group and 0.6% (1/180) in the artemether-lumefantrine group. ALT elevations with increased bilirubin have been observed with pyronaridine-artesunate tablets at a similar incidence in two Phase III studies in *P. falciparum* in 5/1925 (0.3%) patients [5,6]. All cases were in adolescents or adults (14, 23, 25, 39 and 43 years old) and there were no clinical symptoms or evidence of liver injury [5,6]. There were no such cases in a trial of pyronaridine-artesunate in *P. vivax* [7].

Meta-analysis has suggested that pediatric ACT formulations have lower rates of drug-related gastrointestinal adverse events versus tablets [24]. Drug-related gastrointestinal adverse events were more common in a previous trial of adults and children receiving pyronaridine-artesunate tablets (vomiting 3.3%, other gastrointestinal 6.6%) versus artemether-lumefantrine (1.9%, 5.2%, respectively) [5]. This trend was reversed in the current study with pyronaridine-artesunate pediatric granules (vomiting 2.0%, other gastrointestinal 2.0%) versus artemether-lumefantrine crushed tablets (3.3% and 3.9%, respectively).

Pyronaridine-artesunate pediatric granules were efficacious and well tolerated in this study of children under 12 years of age with uncomplicated *P. falciparum* malaria. Considering these data and those of the other Phase III trials [5,6], pyronaridine-artesunate appears to be a valuable new ACT for use in both adults and children with *P. falciparum* malaria.

Additional files

**Additional file 1:** PCR-corrected day-28 adequate clinical and parasitological response rates in the per-protocol population by country and patient age.

**Additional file 2:** Number of patients in the intent-to-treat population with parasite, fever and gametocyte clearance, median clearance times and the proportion of patients with clearance at days 1, 2, and 3.

**Additional file 3:** Key laboratory variables: baseline values, changes from baseline at days 3 and 28, and incidence of post-baseline grade 3 or 4 toxicity values for hepatic enzymes and total bilirubin.

Competing interest

IB-F and SD are employees of the Medicines for Malaria Venture, C-SS is an employee of Shin Poong Pharmaceutical Co. Ltd. There was no conflict of interest for KK, OKD, LKP, ATO, KMB, JK, AKT, JKHT, MR, PMdeS, ABT, AO, MDGB, FQ, or LF.

Authors’ contribution

IB-F, SD, C-SS and LF made substantial contributions to the concept and design of the study. KK, OKD, LKP, ATO, KMB, JK, AKT, JKHT, MR, PMdeS, ABT, AO, MDGB, FQ and LF were involved in the acquisition of data. All authors contributed to the analysis and interpretation of data. All authors critically reviewed the paper and read and approved the final manuscript. In addition to the named authors, the following co-investigators contributed to this study: Bakary Sidibé, Abdoulaye Djimdé (Mali); Berenger A. A. Ako, Aristide M’Lanhorou Coulibaly (Ivory Coast); Moses Omwoyo, Jacqueleen Wanjiru (Kenya); Nsieng Ntamabarya, Raoul Mpoyi Ngambua (Democratic Republic of Congo); Sabine Bélard, Florian Kurth (Gabon); Désiré Kargouguou, David T. Kangoye (Burkina Faso); Jennifer Rabang (Philippines).

Presentation

This study was presented in part at the 5th MIM Pan-African Malaria Conference, Nairobi, Kenya 2–5 November, 2009. Kasoum Kayentao et al. Phase III pivotal trial of pyronaridine artesunate versus artemether-lumefantrine in paediatric patients with acute uncomplicated *Plasmodium falciparum* malaria. Abstract MIM16689930.

Acknowledgements

We thank the study population and local staff, who made this study possible. We would also like to acknowledge the contribution of: Ghiorghis Belai, David Asante, and Pongphaya Hoosakulchart (Family Health International), who were in charge of the study monitoring. Sarah Arbe-Bames, Eric Didillon, Audrey Mulder (FULCUM Pharma, UK) and Claude Oeurvay (MIVL) for their dedicated work in the set-up and execution of this trial. Hanspeter Marti and Hans-Peter Beck (Swiss Tropical and Public Health Institute), who performed the slides central reading and the PCR analysis. We thank Stephen Allen (Swansea University, United Kingdom), Robert Miller (FULCUM Pharma, UK), J Carl Craft (Libertyville, USA), Frank Stephen Wignall (Family Health International) for their participation in the Safety Monitoring Board. Statistical analysis was carried out by DataMap (Freiburg, Germany) and we acknowledge the dedicated work of Martina Wibberg and Carmen Wiesmann with additional analysis by Arnaud Demange (Averion International). Naomi Richardson of Magenta Communications Ltd developed a first draft of this paper from the approved study report and collated author contributions and was funded by the Medicines for Malaria Venture. FULCUM Pharma and Averion International are now part of Aptiv Solutions.

Pyronaridine-artesunate is being developed in a public–private partnership between Shin Poong Pharmaceutical Company Ltd, Seoul, Republic of Korea and the Medicines for Malaria Venture, Geneva, Switzerland. The sponsors and study site principal investigators developed the protocol, interpreted the data and developed the report. The study sponsors were responsible for data collection and statistical analysis. All authors had access to the primary data, take responsibility for data reporting accuracy and completeness and had responsibility for the final decision to submit for publication.

Author details

1Malaria Research and Training Center, Faculté de Médecine de Pharmacie et d’Odonto-Stomatologie, Bamako, Mali. 2Malariology Department, Institut Pasteur, Abdijan, Côte d’Ivoire. 3UNITID, College of Health Sciences, University of Nairobi, Nairobi, Kenya. 4Ecole de Santé Publique, Faculté de Médecine, Université de Kinshasa, Kinshasa, Democratic Republic of Congo. 5Medical Research Unit, Albert Schweitzer Hospital, Lambaréné, Gabon. 6Institute of Tropical Medicine, Tübingen, Germany. 7Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria. 8Center National de Recherche et de Formation sur le Paludisme, Ministère de la Santé, Ouagadougou, Burkina Faso. 9Research Institute for Tropical Medicine, Department of Health, FICC, Alabang, Muntinlupa City, Metro Manila, Philippines. 10Medicines for Malaria Venture, International Center Cointrin, Route de Pré-Bois 20, PO Box 1826 CH-1215 Geneva 15, Switzerland. 11Shin Poong Pharmaceutical, Seoul, South Korea. 12University of Iowa, Iowa City, IA, USA.

Received: 13 August 2012 Accepted: 18 October 2012 Published: 31 October 2012

References

1. Roll Back Malaria Partnership Secretariat: *World malaria Day 2010: Africa Update*. http://www.rollbackmalaria.org/ProgressImpactSeries/docs/wmd2010report-en.pdf.

2. World Health Organization: *World malaria report 2011*. http://www.who.int/malaria/world_malaria_report_2011/en/8924156460_update_20130109.pdf.

3. World Health Organization: Guidelines for the treatment of malaria. second edition. http://www.who.int/medicines/edocs/knowledgeProducts/pdf/malaria_2010.pdf.

4. WHO List of prequalified medicinal products. http://apps.who.int/medicines/edocs/pdf/mep/WHO list of prequalified medicinal products.pdf.

5. Tshefu AK, Gaye O, Kayentao K, Thompson R, Bhattacharjee S, Carael M, Taylor DW, Combley P: Plasmodium falciparum. Abstract MIM16689930.
Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated *Plasmodium falciparum* malaria: a randomised non-inferiority trial. *Lancet* 2010, 375:1457–1467.

6. Rueangweerayut R, Phipho A, Uthaisin C, Vanijanonta S, Wilairatana P, Fleckenstein L. Pyronaridine-artesunate versus mefloquine plus artesunate for malaria. *NEJM* 2012, 366:1298–1309.

7. Poravuth Y, Socheat D, Rueangweerayut R, Pyae P, Uthaisin C, Poravuth Y, Binh T, Tinto H, Pénali L, Fleckenstein L. Pyronaridine-artesunate versus chloroquine in patients with acute *Plasmodium vivax* malaria: a randomised, double-blind, non-inferiority trial. *PloS* One 2011, 6:e14501.

8. Holding PA, Snow RW. Impact of *Plasmodium falciparum* malaria on performance and learning: review of the evidence. *Am J Trop Med Hyg* 2001, 64:68–75.

9. Idro R, Marsh K, John CC, Newton CR. Cerebral malaria: mechanisms of brain injury and strategies for improved neuro-cognitive outcome. *Pediatr Rev* 2010, 64:267–274.

10. Kihara M, de Haan M, Garrashi HH, Neville BG, Newton CR. Atypical brain response to novelty in rural African children with a history of severe falciparum malaria. *J Neural Sci* 2010, 296:88–95.

11. Ramharter M, Kurth F, Belard S, Adegnika AA, Gaye O, Kremsner PG, Ramharter M. Randomised trial of pyronaridine versus artemether-lumefantrine crushed tablets in children with uncomplicated falciparum malaria in Gabon. *J Infect Dis* 2008, 198:911–919.

12. World Health Organization: Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria (WHO/HTM/RBM/2003.50). http://whqlibdoc.who.int/hq/2003/WHO-HTM-RBM_2003.50.pdf.

13. Severe falciparum malaria, World Health Organization: Communicable Diseases Cluster. *Trans R Soc Trop Med Hyg* 2000, 94(Suppl 1):S151–590.

14. Felger I, Beck HP. Genotyping of *Plasmodium falciparum*. PCR-RFLP analysis. *Meth Mol Med.* 2002, 72:117–129.

15. Medicines for Malaria Venture, World Health Organization: Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. http://whqlibdoc.who.int/publications/2008/9789241563655_eng.pdf.

16. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER): Guidance for industry drug-induced liver injury: premarketing clinical evaluation. http://www.fda.gov/downloads/drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174009.pdf.

17. Martensson A, Stromberg J, Siowath C, Moellerm M, Gil JP, Montgomery SM, Olliaro P, Ali AS, Bjorkman A. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood *Plasmodium falciparum* malaria in Zanzibar, Tanzania. *Clin Infect Dis* 2005, 41:1079–1086.

18. Ratcliff A, Siwawanto H, Kenangalem E, Maristela R, Wuxung RM, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. *Lancet* 2007, 369:757–765.

19. Suputturngkol Y, Newton PN, Angus B, Teja-Isavadharm P, Keeratithakul D, Rasamesoraj M, Pukrittayakamee S, White NJ. A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria. *Br J Clin Pharmacol* 2001, 52:655–661.

20. Ringwald P, Bicki J, Basco LK. Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children. *Clin Infect Dis* 1998, 26:946–953.

21. Ringwald P, Bicki J, Basco L. Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa. *Lancet* 1996, 347:224–28.

22. Loosersuwan S, Kute DE, Vitavan C, Varajarajanta S, Wibratana P, Weerarot WH. Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand. *Am J Trop Med Hyg* 1996, 54:205–209.

23. Price R, van Vught M, Phaiupun L, Luxemburger C, Simpson J, McGready R, ter Kule F, Kamh A, Chongsuphajasiddhi T, White NJ, Nosten F. *Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg* 1999, 60:547–555.

24. Kurth F, Belard S, Adegnika AA, Gaye O, Kremsner PG, Ramharter M. Do paediatric drug formulations of artemisinin combination therapies improve the treatment of children with malaria? A systematic review and meta-analysis. *Lancet Infect Dis* 2018, 10:125–132.

Cite this article as: Kayentao et al.: Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with *Plasmodium falciparum* malaria: a randomized controlled trial. *Malaria Journal* 2012 11:364.